Roic.ailogo
Powered by AI
US stock · Healthcare sector · Biotechnology
Company Logo

Catalyst Pharmaceuticals, Inc.

CPRXNASDAQ

16.40

USD
+0.48
(+3.02%)
Market Closed
24.49P/E
9Forward P/E
1.16P/E to S&P500
1.733BMarket CAP
- -Div Yield
SummaryFinancialsTranscriptsMonitoringClassic View
Upcoming Earnings
8 May-12 May
Shares Short
2/28/23
10.37M
Short % of Float
10.77%
Short % of Shares Outs.
9.97%
% Held by Insiders
5.96%
% Held by Institutions
82.04%
Beta
1.16
PEG Ratio
- -
52w. high/low
22.11/6.15
Avg. Daily Volume
2.38M
Return %
Stock
S&P 500
1 year
110.86
(11.55)
3 years
427.15
64.96
5 years
472.66
44.15
Scale: |
High
Low
4.52
1.25
2.84
0.39
2.65
0.54
2.25
0.90
2.27
0.37
3.65
0.41
3.49
1.70
5.80
2.27
2.44
0.51
4.51
1.02
4.08
1.85
7.67
1.85
5.28
2.55
7.58
3.27
19.78
5.24
22.11
13.30
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
- -
- -
- -
0.03
- -
- -
- -
- -
- -
- -
- -
0.00
0.99
1.15
1.36
2.07
Earnings per share
(0.33)
(0.81)
(0.48)
(0.22)
(0.29)
(0.14)
(0.27)
(0.24)
(0.25)
(0.22)
(0.21)
(0.33)
0.31
0.72
0.38
0.80
FCF per share
(0.36)
(0.63)
(0.51)
(0.20)
(0.23)
(0.17)
(0.22)
(0.20)
(0.22)
(0.22)
(0.16)
(0.25)
0.34
0.43
0.57
1.12
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
- -
0.00
0.00
0.00
0.01
0.00
Book Value per sh.
1.30
0.81
0.51
0.30
0.17
0.49
0.47
0.55
0.69
0.47
0.94
0.49
0.85
1.64
2.00
2.91
Comm.Shares outs.
13
13
15
19
22
30
45
64
81
83
86
103
103
104
103
103
Avg. annual P/E ratio
(11.9)
(3.9)
(2.7)
(5.0)
(4.4)
(8.1)
(4.9)
(10.2)
(14.7)
(5.1)
(11.1)
(9.4)
14.2
5.4
13.9
13.0
P/E to S&P500
(0.7)
(0.2)
(0.0)
(0.2)
(0.3)
(0.5)
(0.3)
(0.6)
(0.7)
(0.2)
(0.5)
(0.4)
0.6
0.1
0.5
0.6
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
0
- -
- -
- -
- -
- -
- -
- -
1
102
119
141
214
Operating margin
(Infinity)%
(Infinity)%
(Infinity)%
(823.0)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(7,059.0)%
31.1%
34.7%
37.2%
47.5%
Depreciation (m)
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
Net profit (m)
(4)
(11)
(7)
(4)
(6)
(4)
(12)
(16)
(20)
(18)
(18)
(34)
32
75
39
83
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.6%
(79.0)%
25.0%
20.7%
Net profit margin
(Infinity)%
(Infinity)%
(Infinity)%
(819.4)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(6,800.7)%
31.2%
63.0%
28.0%
38.8%
Working capital (m)
16
10
8
5
5
15
23
38
56
39
81
46
87
136
183
263
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
4
4
Equity (m)
16
11
8
6
4
15
21
35
55
39
81
51
88
170
207
300
ROIC
(25.3)%
(96.5)%
(94.0)%
(72.1)%
(117.8)%
(26.8)%
(52.1)%
(40.6)%
(35.5)%
(44.8)%
(22.1)%
(64.2)%
37.8%
44.2%
18.7%
26.1%
Return on capital
(24.8)%
(85.1)%
(90.5)%
(68.4)%
(102.1)%
(24.2)%
(47.7)%
(35.1)%
(33.5)%
(42.6)%
(21.0)%
(54.1)%
31.1%
21.8%
22.1%
27.9%
Return on equity
(25.4)%
(100.0)%
(95.1)%
(72.6)%
(169.9)%
(27.9)%
(56.8)%
(44.0)%
(36.5)%
(46.0)%
(22.7)%
(67.0)%
36.4%
44.2%
19.1%
27.7%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
20.4%
6.0%
Capital Structure
15 Mar · 2023 | Q4
All numbers in millions
Total liabilities
$ 75
Total assets
$ 376
Long-term debt
$ 4
Cash and equiv.
$ 298
Goodwill
$ - -
Retained earnings
$ 50
Common stock
103
Enterprise Value
$ 1,438
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
140
191
298
Receivables
6
7
10
Inventory
5
8
7
Other
8
45
173
Current assets
159
210
321
Acc. Payable
4
3
4
Debt due
0
0
- -
Other
18
24
54
Current liabilities
23
27
58
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
52.10%
5,112.01%
- -
Cash flow
95.48%
(19.16)%
6.39%
Earnings
110.42%
1.14%
15.39%
Dividends
- -
- -
- -
Book value
45.25%
58.32%
43.89%
Insider Trading
Type
Shares
Date
Coelho Philip H
Award
4,000
02/15/23
Coelho Philip H
Exempt
4,000
02/15/23
Daly Richard J
Exempt
4,000
02/15/23
Daly Richard J
Exempt
4,000
02/15/23
Del Carmen Jeffrey
Exempt
10,666
02/15/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
29
30
29
31
119
2021
30
36
36
38
141
2022
43
53
57
157
310
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.10
0.09
0.42
0.11
0.72
2021
0.07
0.12
0.10
0.09
0.38
2022
0.13
0.21
0.22
0.58
1.14
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Patrick J. McEnany
Full-time employees:
76
City:
Coral Gables
Address:
355 Alhambra Circle
IPO:
Nov 8, 2006
CIK:
0001369568
Website:
catalystpharma.com
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.